Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients
Pediatric Pulmonology · 2026
DOI: 10.1002/ppul.71507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, 2026. Verfasst von Jochen G Mainz und 9 weiteren Autor:innen. Beteiligte Einrichtung: CF-Center, Klinikum Westbrandenburg, Campus Brandenburg an der Havel, Brandenburg an der Havel, Germany. Hauptthemen laut MEDLINE: Cystic Fibrosis, Indoles, Aminophenols, Quinolones. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
Background
For people with cystic fibrosis (pwCF) carrying susceptible mutations, elexacaftor/tezacaftor/ivacaftor (ETI) has changed the course of their lives. Organ manifestations critically affecting both respiratory and digestive tracts have been found to improve considerably. Consequently, ETI‐associated reductions in sinonasal symptoms (SNS) deriving from the upper respiratory tract are consistently reported. However, although substantial ETI‐related declines in the burden of abdominal symptoms (AS) have been reported using the CFAbd‐Score, their correlation with SNS changes has not been studied.
Aims
Assessing correlations between ETI‐related changes in pwCF SNS and AS.
Methods
The German adapted version of the Sinonasal‐Outcome‐Test 20 (SNOT‐20‐GAV) and the CFAbd‐Score, the first CF‐specific gastrointestinal (GI) patient‐reported outcome measure developed and validated following FDA guidelines, were simultaneously administered. PwCF completing both paired questionnaires, at least once before and after ETI initiation, were included.
Results
In two German CF‐centers, n = 31 pwCF (18 f, mean‐age 13 years) were included, completing n = 106 paired questionnaires. During ETI therapy, significant decreases ( p < 0.05) were observed for the mean total CFAbd‐Score (10.9→5.8pts[−47%]) as well as all sub‐scores (‘pain’: −61%, ‘disorders of bowel movement’: −56%, ‘GERD’: −54%, ‘disorders of appetite’: −50% and ‘QoL‐impairment’:−67%). Analogously, SNS significantly improved (total SNOT: 10.1→3.4pts[−66%] and its 3 domains: primary and secondary nasal symptoms, and SNS‐related QoL [−68%/−81%/−54%]). However, the correlation between changes in symptoms related to upper‐respiratory and GI tracts was only modest.
Conclusion
The burden of symptoms captured with the CFAbd‐Score and the SNOT‐20‐GAV significantly and markedly decreased after ETI initiation. The modest association between changes in both organ‐specific symptom scores supports the previously reported individualized electrophysiological responses observed in nasal‐potential and intestinal‐current measurements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CF-Center, Klinikum Westbrandenburg, Campus Brandenburg an der Havel, Brandenburg an der Havel, Germany.
- Medizinische Hochschule Brandenburg (MHB), Universitätsklinikum, Brandenburg an der Havel, Germany.
- Department of Otorhinolaryngology, University Hospital Heidelberg, Heidelberg, Germany.
- Department of Gastroenterology, Brandenburg Medical School (Theodor Fontane), Brandenburg an der Havel, Germany.
- Department of Pediatrics, Division of Pneumology, Allergology, Infectious Diseases, Gastroenterology, Goethe University, Frankfurt a.M., Germany.
ORCID-Profile: Olaf Eickmeier, Carlos Zagoya
Zitieren
APA
Mainz, J. G., Greiner, V., Sadrieh, P., Polte, L., Baumann, I., Duckstein, F., Barucha, A., van Dullemen, S., Eickmeier, O., & Zagoya, C. (2026). Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71507
Vancouver
Mainz JG, Greiner V, Sadrieh P, Polte L, Baumann I, Duckstein F, et al. Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71507
BibTeX
@article{Mainz2026,
author = {Mainz, Jochen G and Greiner, Vivien and Sadrieh, Pauline and Polte, Louise and Baumann, Ingo and Duckstein, Franziska and Barucha, Anton and van Dullemen, Suzanne and Eickmeier, Olaf and Zagoya, Carlos},
title = {Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients},
journal = {Pediatric Pulmonology},
year = {2026},
doi = {10.1002/ppul.71507}
}
EUVIMED